U.S. Depyrogenated Sterile Empty Vials Market Size, Share & Trends Analysis Report By Product (2 ml, 5 ml, 10 ml, 20 ml), By End Use (Clinical Labs, Componding Pharmacies), And Segment Forecasts, 2018 - 2025

Published: Oct, 2018 | Pages: 71 | Publisher: Grand View Research
Industry: Medical Devices | Report Format: Electronic (PDF)

The U.S. depyrogenated sterile empty vials market size is likely to reach USD 3.5 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 5.2% during the forecast period. Technological advancements in pharmaceutical packaging process, growing funding by government organizations, and flourishing biologics market in the U.S. are some of the key trends escalating market growth. Stringent regulations laid by the government for parenteral are also poised to augment the market.

Rising number of clinical labs in the country is resulting in an increased number of medical and diagnostic tests. This, in turn, is fueling the demand for depyrogenated sterile empty vials. Increasing number of compounding laboratories and research institutes in the U.S. is boosting the demand for these vials in the market. Moreover, continual growth in the pharmaceutical and biotechnology industry is further projected to drive the market.

Increasing number of collaborations in order to achieve innovative packaging technology is also providing an upthrust to the market. Rising incidence of infectious & non-infectious diseases and growing number of clinical studies are translating into a greater demand for these vials. Besides this, the government is backing the promotion of pharmaceutical, medical, and biotechnological researches, which is anticipated to work in favor of the market.

Further key findings from the report suggest:

• More than 20 ml depyrogenated sterile empty vials emerged as the largest segment in terms of revenue in 2017 owing to rising incidence of infectious & non-infectious diseases and increasing investments in the biopharmaceutical sector

• Others, which include pharmaceutical manufacturers and academic & research institutes, formed the most prominent end-use segment in 2017. The growth of the segment can be attributed to expanding base of medical & biotech research institutes and upswing in pharmaceutical manufacturing

• Thermo Fisher Scientific, Inc.; Gerresheimer AG; SCHOTT AG; and DWK Life Sciences are the major players operating in the market. This market is considerably fragmented and market entry barrier is high.

 Table of Contents

Chapter 1 Research Methodology
                 1.1 Information Procurement
                     1.1.1 Purchased database:
                     1.1.2 GVR's internal database
                 1.2 Primary Research:
                     1.2.1 List of primary sources include:
Chapter 2 Executive Summary
                 2.1 Market Snapshot (USD Million), 2017
Chapter 3 U.S. Depyrogenated Sterile Empty Vials Market Variables, Trends & Scope
                 3.1 Market Segmentation & Scope
                 3.2 Market Driver Analysis
                     3.2.1 Technological advancements
                     3.2.2 Growth in pharmaceutical sector
                     3.2.3 Growing compounding pharmacies and clinical laboratories in the U.S.
                 3.3 Market Restraint Analysis
                     3.3.1 Growing demand for other parenteral packaging alternatives
                 3.4 Penetration & Growth Prospect Mapping
                 3.5 End Use Product Adoption/ Product Penetration Analysis
                 3.6 Pricing Analysis by Brand
                 3.7 U.S. Depyrogenated Sterile Empty Vials Market - SWOT Analysis, By Factor (political & legal, economic and technological)
                 3.8 Industry Analysis - Porter's
Chapter 4 U.S. Depyrogenated Sterile Empty Vials Market: Product Estimates & Trend Analysis
                 4.1 U.S. Depyrogenated Sterile Empty Vials Market: Product Movement Analysis, 2017 & 2025
                 4.2 2mL Vials
                     4.2.1 2mL vials market revenue estimates and forecasts, 2014 - 2025 (USD Million)
                     4.2.2 2mL vials market volume estimates and forecasts, 2014 - 2025 (Million units)
                 4.3 5mL Vials
                     4.3.1 5mL vials market revenue estimates and forecasts, 2014 - 2025 (USD Million)
                     4.3.2 5mL vials market volume estimates and forecasts, 2014 - 2025 (Million units)
                 4.4 10mL Vials
                     4.4.1 10mL vials market revenue estimates and forecasts, 2014 - 2025 (USD Million)
                     4.4.2 10mL vials market volume estimates and forecasts, 2014 - 2025 (Million units)
                 4.5 20 ml Vials
                     4.5.1 20 ml vials market revenue estimates and forecasts, 2014 - 2025 (USD Million)
                     4.5.2 20 ml vials market volume estimates and forecasts, 2014 - 2025 (Million units)
                 4.6 More than 20 ml Vials
                     4.6.1 More than 20 ml vials market revenue estimates and forecasts, 2014 - 2025 (USD Million)
                     4.6.2 More than 20 ml vials market volume estimates and forecasts, 2014 - 2025 (Million units)
Chapter 5 U.S. Depyrogenated Sterile Empty Vials Market: End use Estimates & Trend Analysis
                 5.1 U.S. Depyrogenated Sterile Empty Vials Market: End use Movement Analysis, 2017 & 2025
                 5.2 Clinical Laboratories
                     5.2.1 Clinical laboratories market revenue estimates and forecasts, 2014 - 2025 (USD Million)
                 5.3 Compounding Pharmacies
                     5.3.1 Compounding pharmacies market revenue estimates and forecasts, 2014 - 2025 (USD Million)
                 5.4 Other End uses
                     5.4.1 Other end uses market revenue estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 6 Company Profiles
                 6.1 Participant categorization
                 6.2 Heat Map Analysis
                 6.3 Company Profiles
                     6.3.1 Thermo Fisher Scientific, Inc.
                         6.3.1.1 Company overview
                         6.3.1.2 Financial performance
                         6.3.1.3 Product benchmarking
                         6.3.1.4 Strategic initiatives
                     6.3.2 VWR International, LLC
                         6.3.2.1 Company overview
                         6.3.2.2 Financial performance
                         6.3.2.3 Product benchmarking
                         6.3.2.4 Strategic initiatives
                     6.3.3 Stevanato Group
                         6.3.3.1 Company overview
                         6.3.3.2 Financial performance
                         6.3.3.3 Product benchmarking
                         6.3.3.4 Strategic initiatives
                     6.3.4 SiO2 Medical Products, Inc.
                         6.3.4.1 Company overview
                         6.3.4.2 Financial performance
                         6.3.4.3 Product benchmarking
                         6.3.4.4 Strategic initiatives
                     6.3.5 DWK Life Sciences
                         6.3.5.1 Company overview
                         6.3.5.2 Financial performance
                         6.3.5.3 Product benchmarking
                         6.3.5.4 Strategic initiatives
                     6.3.6 Merck KGaA
                         6.3.6.1 Company overview
                         6.3.6.2 Financial performance
                         6.3.6.3 Product benchmarking
                     6.3.7 Gerresheimer AG
                         6.3.7.1 Company overview
                         6.3.7.2 Financial performance
                         6.3.7.3 Product benchmarking
                         6.3.7.4 Strategic initiatives
                     6.3.8 Corning, Inc.
                         6.3.8.1 Company overview
                         6.3.8.2 Financial performance
                         6.3.8.3 Product benchmarking
                         6.3.8.4 Strategic initiatives
                     6.3.9 SCHOTT Corporation
                         6.3.9.1 Company overview
                         6.3.9.2 Financial performance
                         6.3.9.3 Product benchmarking
                         6.3.9.4 Strategic initiatives